Search PubMed⌕ Search

Biomedical subjects

J Rouffy

Publications and source records attributed to J Rouffy.

At least 91 records · Page 5Linked to original sources
PubMed1976

[Type IIb primary hyperlipoproteinemia. An homogenous series of 412 cases].

On the basis of a homogeneous series of 412 cases of type IIb primary hyperlipoproteinaemia, the authors compare their experience with findings in the literature. The prevalence of this type of hyperlipoproteinaemia in the general population has been underestimated at 3%. Biological diagnosis remains simple (identification of a double and distinct excess in beta and pre beta lipoproteins). Extravascular lipid deposits (gerontoxon, xanthelasma, tendon xanthomata) are not type specific. Hyperlipidaemic syndrome is rare. Above all, the importance of type IIb in atheromatous disease in the young subject now seems obvious. The mode of hereditary transmission of the familial anomaly is not certain but would appear to be often associated with a double heterozygote condition.

Cholesterol↗
PubMed1976

Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).

The effect of isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF 178; procetofene; Lipanthyl), a new hypolipidemic agent, has been evaluated in 191 patients affected by endogenous hyperlipoproteinemia (IIa, IIb and IV). Data were collected from patients on active drug trial from 1 to 18 months. The daily administered dose varied from 200 to 400 mg according to pretreatment dietary stabilized lipid values. Under the controlled experimental conditions described, LF-178 lowered cholesterol by 20 to 36% in types IIa and IIb and triglycerides by 30 to 50% in types IIa and IV of H. L. P. A comparative trial of LF 178 and clofibrate indicates that the drug is significantly more potent than the reference compound after 1 month of treatment. Tolerance has always been excellent throughout the study.

Clinical Trials as Topic↗
PubMed1976

[Hyperlipoproteinemias in psoriasis].

The hyperlipoproteinaemia truly characteristic of psoriasis is the type IV or major endogenous hypertriglyceridaemia. It is found in 39 p. 100 of patients with psoriasis as compared to 18 p. 100 of our controls (though 6 p. 100 of the French population according to Turpin and De Gennes). It appears to be definitely genotypic, environmental factors playing only a minor role. This study would tend to integrate psoriasis into the category of the metabolic diseases, coinciding with the notion of troubles with glucose metabolism in psoriatics, since it is now accepted that 80 p. 100 of type IV hyperlipoproteinaemias are pre-diabetic.

Adolescent↗
PubMed1975

[Biological examination in hyperlipemia].

The authors review the various methods of investigation useful in the classification of hyperlipoproteinaemias. Estimation of cholesterol and triglycerides remain the most important elements but do not suffice alone to reach a conclusion and measurement of phospholipids would seem to be a useful addition. Electrophoresis on agar, isolating a larger quantity of prebetalipoproteins, does not always facilitate classification. Finally, ultracentrifugation is often necessary in those forms which are difficult to classify, these representing almost 20 p.cent of patients.

Cholesterol↗